The LARK trial will look at treatment outcomes and treatment efficiency when incorporating KIM with SABR to treat eligible patients with primary or secondary liver cancer. Participants will have fiducial markers inserted around their tumours to allow the KIM system to track tumour movement as the patient breathes.
Project status: Open to recruitment.
Study size: 46 patients
Sites: Westmead Hospital, Nepean Hospital, Princess Alexandra Hospital.
Collaborating Group: TROG Cancer Research
Contact: Doan Trang Nguyen [email protected]